Dr. McGrath graduated from Trinity College Dublin in 1998. He undertook house officer jobs at St. James’s Hospital Dublin before being appointed to the Federated Hospitals of Dublin Senior House Officer Training Scheme. After completing MRCPI in 2001, he was appointed as a respiratory registrar at the Professorial Unit, St. Vincent’s University Hospital Dublin. From here, he moved to the SpR training scheme in respiratory medicine in Sheffield. In 2005, he was awarded a Wellcome Clinical Training Fellowship to investigate the role of TNF-related apoptosis inducing ligand (TRAIL) in inflammation in vivo under the supervision of Professor Moira Whyte. He was awarded a PhD from the University of Sheffield and was appointed as an NIHR Clinical Lecturer in Respiratory Medicine in 2009. In November 2010, he moved to the University of Birmingham to continue his work as a Senior Clinical Lecturer in Respiratory Medicine.
He is clinical lead for interstitial lung disease at Birmingham Heartlands Hospital and runs specialist clinics in this area at the Birmingham Chest Clinic. He is also involved in multi-centre clinical trials in the treatment of IPF.
Previous work at Professor Moira Whyte’s lab in Sheffield had shown that TRAIL induced neutrophil apoptosis in vitro. Dr. McGrath’s research has focused on the role of TRAIL in vivo in inflammatory lung disease including acute respiratory distress syndrome (ARDS) and idiopathic pulmonary fibrosis (IPF), specifically its role in neutrophil lifespan and disease severity. His work which demonstrated that TRAIL has biomarker and therapeutic potential in inflammatory lung disease has been published and presented at numerous international meetings leading to travel and young investigator awards from the ATS, ERS, ITS and British Lung Foundation.
McGrath EE, Lawrie A, Marriott HM, Mercer P, Cross SS, Arnold N, Singleton V, Thompson AA, Walmsley SR, Renshaw SA, Sabroe I, Chambers RC, Dockrell DH, Whyte MK.Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. Thorax. 2012 Apr 11. [Epub ahead of print]
McGrath EE, Warriner D, Anderson PB. The insertion of self expanding metal stents under sedation with flexible bronchoscopy for malignant tracheobronchial stenosis: a single center experience. Arch Bronconeumol 2012- in press
McGrath EE, Millar AB. Hot off the breath: Triple therapy for IPF- hear the PANTHER roar. Thorax Feb 2012- in press.
McGrath EE. The OPG/RANKL/RANK Pathway as a Therapeutic Target. J Thorac Oncol2011 Sep;6(9):1468-73.
McGrath EE, Warriner D, Anderson PB. Is There a Beneficial Role for a Flexible Bronchoscopic Approach to Oesophageal Tumour Related Tracheobronchial Stenosis? Lung. 2011 Oct;189(5):401-7.
McGrath EE. The TNF-Related Apoptosis Inducing Ligand and Lung Cancer: Still on the Right TRAIL? J Thorac Oncol. 2011 Jun;6(6):983-7.
McGrath EE, Marriott HM, Francis S, Renshaw SA, Dockrell DH, Whyte MKB. TNF-Related Apoptosis Inducing Ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol. 2011 Nov;90(5):855-65.
McGrath EE, Anderson PB. Investigating a pleural effusion: a systematic approach. Am J Crit Care. 2011 Mar;20(2):119-27
McGrath EE, Anderson PB. The therapeutic approach to non-tuberculous mycobacterial infection of the lung. Pulm Pharmacol Ther. 2010 Oct;23(5):389-96.